The heightened importance of the microbiome in cancer immunotherapy DOI Creative Commons

C Villemin,

Anne Six,

Bridget A. Neville

et al.

Trends in Immunology, Journal Year: 2022, Volume and Issue: 44(1), P. 44 - 59

Published: Dec. 1, 2022

The human microbiome is recognized as a key factor in health and disease. This has been further corroborated by identifying changes composition function novel hallmark cancer. These effects are exerted through interactions with host cells, impacting wide variety of developmental physiological processes. In this review, we discuss some the latest findings on how bacterial component can influence outcomes for different cancer immunotherapy modalities, highlighting identified mechanisms action. We also address clinical efforts to utilize knowledge achieve better responses immunotherapy. A refined understanding variations patients microbiome–host therapies essential realize optimal responses.

Language: Английский

Gut microbiota: A new insight into lung diseases DOI Open Access
Peijun Ma, Mengmeng Wang, Yun Wang

et al.

Biomedicine & Pharmacotherapy, Journal Year: 2022, Volume and Issue: 155, P. 113810 - 113810

Published: Oct. 8, 2022

The human gut microbiota is a complex ecosystem involved in the metabolism, immunity, and health of host. microbiome plays key role development host's innate adaptive immune system, while system orchestrates maintenance host-microbe symbiosis. Lung diseases are usually accompanied by dysbiosis intestinal flora an immune-inflammatory response. its metabolites directly or indirectly regulation host lung disease. However, exact mechanism action gut-lung axis crosstalk remains unclear. This review aimed to summarize latest advances their typical diseases, such as pulmonary hypertension, COPD, cancer. Especially COVID-19, problem troubling world, also discussed it. Moreover, it concentrated on mechanisms between identified specific link among microbiota, metabolites, regulation, which could be used breakthrough find new targets for some without therapeutic drugs clinic. It tool "drug-bacterial interaction" potential applications would provide clear direction future research propose strategy targeting

Language: Английский

Citations

86
Gut Microbiota-Derived Short-Chain Fatty Acids: Impact on Cancer Treatment Response and Toxicities DOI Creative Commons
Ghanyah Al-Qadami, Kate R. Secombe, Courtney B. Subramaniam

et al.

Microorganisms, Journal Year: 2022, Volume and Issue: 10(10), P. 2048 - 2048

Published: Oct. 17, 2022

The gut microbiota has emerged as a key modulator of cancer treatment responses in terms both efficacy and toxicity. This effect is clearly mediated by processes impacting the activation modulation immune responses. More recently, ability to regulate chemotherapeutic drug metabolism also driver response, although direct mechanisms have yet be fully elucidated. Through fermentation, can produce several types metabolites, including short-chain fatty acids (SCFAs). SCFAs play an important role maintaining epithelial barrier functions intestinal homeostasis, with recent work suggesting that modulate response treatments influence anti-tumor inflammatory-related side effects. In this review, we will discuss importance their implications for toxicities.

Language: Английский

Citations

81
Towards modulating the gut microbiota to enhance the efficacy of immune-checkpoint inhibitors DOI
Rebecca Simpson, Erin R. Shanahan, Richard A. Scolyer

et al.

Nature Reviews Clinical Oncology, Journal Year: 2023, Volume and Issue: 20(10), P. 697 - 715

Published: July 24, 2023

Language: Английский

Citations

57
Role of gut microbiome in cancer immunotherapy: from predictive biomarker to therapeutic target DOI Creative Commons

Mengwei Zhang,

Jinkai Liu,

Qiang Xia

et al.

Experimental Hematology and Oncology, Journal Year: 2023, Volume and Issue: 12(1)

Published: Sept. 28, 2023

Immunotherapy has emerged as an effective treatment for various types of cancers. Recent studies have highlighted a significant correlation between the gut microbiome and patients' response to immunotherapy. Several characteristics microbiome, such community structures, taxonomic compositions, molecular functions, been identified crucial biomarkers predicting immunotherapy immune-related adverse events (irAEs). Unlike other -omics, can serve not only but also potential targets enhancing efficacy Approaches modulating include probiotics/prebiotics supplementation, dietary interventions, fecal microbiota transplantation (FMT), antibiotic administration. This review primarily focuses on elucidating role in cancer improving its efficacy. Notably, we explore reasons behind inconsistent findings observed different studies, highlight underlying benefits antibiotics liver

Language: Английский

Citations

52
Modulating gut microbiome in cancer immunotherapy: Harnessing microbes to enhance treatment efficacy DOI Creative Commons
Xing Kang, Harry Cheuk-Hay Lau, Jun Yu

et al.

Cell Reports Medicine, Journal Year: 2024, Volume and Issue: 5(4), P. 101478 - 101478

Published: April 1, 2024

Immunotherapy has emerged as a robust approach against cancer, yet its efficacy varied among individuals, accompanied by the occurrence of immune-related adverse events. As result, immunotherapy is far from satisfactory, and enormous efforts have been invested to develop strategies improve patient outcomes. The gut microbiome now well acknowledged for critical role in immunotherapy, with better understanding on host-microbes interaction context cancer treatment. Also, an increasing number trials conducted evaluate potential feasibility microbiome-targeting approaches enhance treatment patients. Here, metabolites (e.g., short-chain fatty acids, tryptophan metabolites) underlying mechanisms are explored. application that aim fecal microbiota transplantation, probiotics, dietary intervention) also elaborated, further discussion current challenges suggestions future research.

Language: Английский

Citations

47
Multi-kingdom gut microbiota analyses define bacterial-fungal interplay and microbial markers of pan-cancer immunotherapy across cohorts DOI Creative Commons
Xiaowen Huang,

Muni Hu,

Tiantian Sun

et al.

Cell Host & Microbe, Journal Year: 2023, Volume and Issue: 31(11), P. 1930 - 1943.e4

Published: Nov. 1, 2023

Language: Английский

Citations

44
Fatty acid metabolism of immune cells: a new target of tumour immunotherapy DOI Creative Commons
Sheng Zhang,

Kebing Lv,

Zhen Yu Liu

et al.

Cell Death Discovery, Journal Year: 2024, Volume and Issue: 10(1)

Published: Jan. 20, 2024

Language: Английский

Citations

39
Butyrate as a promising therapeutic target in cancer: From pathogenesis to clinic (Review) DOI Creative Commons

Jinzhe Sun,

Shiqian Chen,

Dan Zang

et al.

International Journal of Oncology, Journal Year: 2024, Volume and Issue: 64(4)

Published: Feb. 29, 2024

Cancer is one of the leading causes mortality worldwide. The etiology cancer has not been fully elucidated yet, and further enhancements are necessary to optimize therapeutic efficacy. Butyrate, a short‑chain fatty acid, generated through gut microbial fermentation dietary fiber. Studies have unveiled relevance butyrate in malignant neoplasms, comprehensive understanding its role imperative for realizing full potential oncological treatment. Its antineoplastic effects via activation G protein‑coupled receptors inhibition histone deacetylases also confirmed. However, underlying mechanistic details remain unclear. present study aimed review involvement carcinogenesis molecular mechanisms, with particular emphasis on association efficacy tumor immunotherapy, as well discussing relevant clinical studies target neoplastic diseases provide new insights into

Language: Английский

Citations

37
Gut microbiota reshapes cancer immunotherapy efficacy: Mechanisms and therapeutic strategies DOI Creative Commons
Jindong Xie, Manqing Liu, Xinpei Deng

et al.

iMeta, Journal Year: 2024, Volume and Issue: 3(1)

Published: Jan. 1, 2024

Abstract Gut microbiota is essential for maintaining local and systemic immune homeostasis in the presence of bacterial challenges. It has been demonstrated that play contrasting roles cancer development as well anticancer immunity. Cancer immunotherapy, a novel therapy relies on stimulation host immunity, suffered from low responding rate incidence severe immune‐related adverse events (irAEs). Previous studies have diversity composition gut were associated with heterogeneity therapeutic effects. Therefore, alteration taxa can lead to improved clinical outcomes immunotherapy. In this review, we determine whether or microbiota‐derived metabolites are linked responses immunotherapy irAEs. Moreover, discuss various approaches improve efficacy reduce toxicities by modulating composition.

Language: Английский

Citations

31
Gut–X axis DOI Creative Commons
Lin Xu, Yu Zhang, Xueyan Li

et al.

iMeta, Journal Year: 2025, Volume and Issue: 4(1)

Published: Feb. 1, 2025

Abstract Recent advances in understanding the modulatory functions of gut and microbiota on human diseases facilitated our focused attention contribution to pathophysiological alterations many extraintestinal organs, including liver, heart, brain, lungs, kidneys, bone, skin, reproductive, endocrine systems. In this review, we applied “gut–X axis” concept describe linkages between other organs discussed latest findings related axis,” underlying mechanisms potential clinical intervention strategies.

Language: Английский

Citations

2